Bhavnagar (Gujarat) manufacturer of antacid-segment Active Pharmaceutical Ingredients (APIs) and Fine Chemicals, now exiting this business to diversify into real estate/construction, capital markets and renewable energy.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 6 | 6 | 12 | 12 | 12 | 12 | 12 | 12 |
| Reserves | 34 | 46 | 48 | 59 | 73 | 87 | 94 | 100 |
| Borrowings | 6 | 8 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 13 | 16 | 19 | 18 | 16 | 20 | 21 | 17 |
| Total Liabilities | 60 | 76 | 79 | 89 | 102 | 119 | 128 | 129 |
| AssetsFixed Assets | 34 | 30 | 34 | 38 | 41 | 39 | 38 | 36 |
| CWIP | 1 | 5 | 0 | 0 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 25 | 27 | 27 |
| Other Assets | 25 | 42 | 44 | 50 | 60 | 55 | 63 | 65 |
| Total Assets | 60 | 76 | 79 | 89 | 102 | 119 | 128 | 129 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 2 | 8 | 12 | 8 | 13 | 20 | 16 | 16 |
| Cash from Investing | 0 | -1 | 0 | -3 | -7 | -6 | -25 | -2 |
| Cash from Financing | -2 | 1 | 2 | -10 | 0 | 0 | 0 | 0 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 2 | 6 | 12 | 4 | 6 | 14 | 15 | 14 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (37.2×) and current (44.5×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 10% growth and a 37× exit, ₹94 only delivers your return if you pay ₹54. The price is currently baking in 22% growth.
EPS grows 10%/yr for 5 years, then fades to 6% over 2, exits at 37×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 10.0% | 2.32 |
| FY28 | 10.0% | 2.55 |
| FY29 | 10.0% | 2.81 |
| FY30 | 10.0% | 3.09 |
| FY31 | 10.0% | 3.40 |
| FY32 | 8.0% ·fade | 3.67 |
| FY33 | 6.0% ·fade | 3.89 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.